Pharming Group N.V.
PHAR
$16.20
-$0.01-0.06%
NASDAQ
| 06/30/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | 93.22M | 92.67M | 74.85M | 74.09M | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 93.22M | 92.67M | 74.85M | 74.09M | |
| Cost of Revenue | 8.97M | 12.21M | 6.82M | 7.98M | |
| Gross Profit | 84.25M | 80.46M | 68.03M | 66.11M | |
| SG&A Expenses | 57.25M | 46.56M | 43.98M | 48.55M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -1.85M | -143.00K | -777.00K | -912.00K | |
| Total Operating Expenses | 90.17M | 80.94M | 70.74M | 77.21M | |
| Operating Income | 3.05M | 11.73M | 4.11M | -3.12M | |
| Income Before Tax | 7.08M | 6.68M | 1.51M | -60.00K | |
| Income Tax Expenses | 2.53M | 3.82M | 2.55M | 1.16M | |
| Earnings from Continuing Operations | 4.55M | 2.86M | -1.03M | -1.22M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | 144.00K | -- | -- | -- | |
| Net Income | 4.69M | 2.86M | -1.03M | -1.22M | |
| EBIT | 3.05M | 11.73M | 4.11M | -3.12M | |
| EBITDA | 4.28M | 19.43M | 8.58M | -1.17M | |
| EPS Basic | 0.01 | 0.00 | 0.00 | 0.00 | |
| Normalized Basic EPS | 0.00 | 0.01 | -- | 0.00 | |
| EPS Diluted | 0.01 | 0.00 | 0.00 | 0.00 | |
| Normalized Diluted EPS | 0.00 | 0.01 | -- | 0.00 | |
| Average Basic Shares Outstanding | 686.44M | 740.00M | 517.00M | 688.98M | |
| Average Diluted Shares Outstanding | 686.44M | 740.00M | 517.00M | 688.98M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |